Relationship of acute mania symptomatology to maintenance treatment response

The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive (Mail Code 7792), San Antonio, TX 78229, USA.
Current Psychiatry Reports (Impact Factor: 3.24). 12/2004; 6(6):473-7. DOI: 10.1007/s11920-004-0013-0
Source: PubMed


Most treatment of bipolar disorders addresses maintenance objectives. In the past 4 years, several large, blinded, randomized, placebo-controlled maintenance studies involving more than 3000 patients with bipolar I illness have been published, with analyses of background, symptomatic, and acute treatment factors contributing to maintenance effectiveness. This article summarizes these findings. Generally, indices of greater severity predict lower response rates to most monotherapy treatments. Some findings have been unexpected. Mixed mania did not predict different maintenance response to divalproex or lithium but predicted more side effects with either drug, and reduced efficacy of olanzapine or lamotrigine.

1 Read
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: This review aims to outline the evidence for the acute and long term efficacy and tolerability of valproate in the management of bipolar disorders, in both adults and adolescent populations. Additionally, determinants of favorable or unfavorable outcomes are described. Method: The authors reviewed published studies and abstracts from 2000 onwards. Emphasis was placed on randomized, placebo-controlled prospective studies. Result: Recent studies hypothesize valproate's inhibition of histone deacetylase and glycogen synthase kinase, and activation of extracellular signal-regulated kinase to be relevant to its actions in bipolar disorders and overlap with postulated mechanism of actions of lithium. Valproate demonstrates both efficacy and tolerability in the treatment of acute mania, and is somewhat more effective in certain patient subgroups, for example, mixed mania, and mania with prominent irritability, in comparison to other treatments. Valproate demonstrates comparable efficacy but superior tolerability to olanzapine in maintenance treatment. Serum levels greater than 110 μg/ml are associated with higher prevalence of weight gain, sedation, and thrombocytopenia. Valproate may be associated with an increased rate of polycystic ovarian syndrome, with higher risks in those with increased weight. Several studies indicate that valproate can be safely and beneficially combined with antipsychotic drugs and other treatments for bipolar disorder. Conclusion: Valproate continues to be studied in further clarification of its mechanisms, efficacy, risks, and spectrum of benefits in bipolar disorder. Evidence from studies in the past two decades demonstrates that valproate is a major treatment, both as monotherapy and in combination with other agents, for the acute and long term treatment of bipolar disorders.
    Bipolar Psychopharmacotherapy: Caring for the Patient, 05/2006: pages 27 - 42; , ISBN: 9780470017951
  • [Show abstract] [Hide abstract]
    ABSTRACT: Up to 50% of first-episode psychosis patients suffer from long-term incomplete remission or treatment resistance. Different definitions for these terms have been used in psychiatric research, making generalized statements about the prevalence and predictors of treatment resistance difficult. The aim of this study was to give an overview on state-of-the-art definitions of treatment resistance for each of the diagnoses making up the inhomogeneous diagnostic entity 'psychosis' and to analyze the factors leading to treatment resistance. A computerized and manual literature search for relevant articles published within recent years was undertaken. In addition to symptomatic criteria, patients' functional level and quality of life have to be considered in the definition of treatment resistance. Patient-related, illness-related and treatment-related predictors of treatment resistance and incomplete remission might help to identify subjects at risk and optimize interventions.
    Expert Opinion on Pharmacotherapy 09/2008; 9(12):2027-38. DOI:10.1517/14656566.9.12.2027 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Several treatment guidelines are available for clinicians working with patients with bipolar disorder (BD), but some of the more nuanced aspects of lithium therapy go beyond the scope of such guidelines. Therefore, in this perspective, our objective was to focus on specific practical issues of lithium treatment, including the selection and initiation of long-term treatment, and management and discontinuation (if indicated) of lithium prophylaxis. Method: We conducted a focused review of the relevant literature on the treatment of BD. Results: Consultation requests to a BD specialty service often relate to issues for which there is limited evidence, including when to initiate long-term treatment, whether choice of mood stabilizer is specific, how long to treat acute episodes, whether to switch or add on medication when treatment fails, how long to continue effective treatment, and what medication to use when a lithium-responsive patient must discontinue lithium. Conclusion: Optimal long-term treatment of BD will require more research as well as better alignment of clinical and training programs.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie 07/2012; 57(7):437-45. · 2.55 Impact Factor